Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates

Fumaric Acid Microenvironment Tablet Formulation and Process Development for Crystalline Cenicriviroc Mesylate, a BCS IV Compound

(2013) Mark M. Menning et al.   MOLECULAR PHARMACEUTICS

Baseline susceptibility of primary HIV-2 to entry inhibitors

(2012) Pedro Borrego et al.   ANTIVIRAL THERAPY

Long-term maraviroc use as salvage therapy in HIV-2 infection

(2012) U. Caixas et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In VitroPhenotypic Susceptibility of HIV-2 Clinical Isolates to CCR5 Inhibitors

(2011) Benoit Visseaux et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics and Pharmacodynamics of TBR-652, a Novel CCR5 Antagonist, in HIV-1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients

(2011) Jean-Francois Marier et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Safety, Efficacy, and Pharmacokinetics of TBR-652, a CCR5/CCR2 Antagonist, in HIV-1–Infected, Treatment-Experienced, CCR5 Antagonist–Naive Subjects

(2011) Jacob Lalezari et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc

(2010) Darius Armstrong-James et al.   ANTIVIRAL RESEARCH

Coreceptor usage by HIV-1 and HIV-2 primary isolates: The relevance of CCR8 chemokine receptor as an alternative coreceptor

(2010) M. Calado et al.   VIROLOGY

Foscarnet as salvage therapy in HIV-2-infected patient with antiretroviral treatment failure

(2009) Sophie Stegmann et al.   JOURNAL OF CLINICAL VIROLOGY

In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors

(2008) D. Desbois et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro

(2008) B. Roquebert et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY